| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Company Drives Significant Increases in Test Volume and Ordering Providers with Florida Becoming Second Medicaid State Covering Test |
| 19 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This Employment Agreement (this “Agreement”) is effective for all purposes as of August 14, 2026 (the “Effective Date”), by and between Sera Prognostics, Inc., a Delaware corporation (the “Company”), and Scott Gleason (the “Employee”). |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today ann... |
| 30 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Non-employee members of the board of directors (the “Board”) of Sera Prognostics, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash an... |
| 04 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 4, 2026, Sera Prognostics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) via live audio webcast on the Internet. Of the 38,190,966 shares of Class A common stock, par value $0.0001 per s... |
| 01 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Salt Lake City – June 1, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announ... |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
Salt Lake City – May 6, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announc... |
| 18 Mar 2026 |
8-K: Results of Operations and Financial Condition
Salt Lake City – March 18, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today anno... |
| 08 Jan 2026 |
8-K: Regulation FD Disclosure
JANUARY 2026 We are redefining pregnancy care to reduce the burden of preterm birth |
| 07 Jan 2026 |
8-K: Regulation FD Disclosure
Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions. |
| 24 Nov 2025 |
8-K: Regulation FD Disclosure
The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Salt Lake City – November 13, 2025 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today a... |
| 05 Sep 2025 |
8-K: Regulation FD Disclosure
September 2025 We are redefining pregnancy care to reduce the burden of preterm birth Exhibit 99.1 |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
Salt Lake City – August 6, 2025 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today anno... |
| 05 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 5, 2025, Sera Prognostics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) via live audio webcast on the Internet. Of the 36,701,381 shares of Class A common stock, par value $0.0001 per s... |
| 08 May 2025 |
8-K: Regulation FD Disclosure
Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
Salt Lake City – May 7, 2025 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announc... |
| 19 Mar 2025 |
8-K: Results of Operations and Financial Condition
Salt Lake City – March 19, 2025 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today anno... |
| 12 Feb 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
Introductory. Sera Prognostics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A attached hereto (the “Underwriters”) an aggregate of (i) 1,250,000 shares of the Com... |
| 10 Feb 2025 |
8-K: Other Events
Pursuant to that certain sales agreement, dated August 7, 2024 (the “Sales Agreement”), that Sera Prognostics, Inc. (the “Company”) entered into with TD Securities (USA) LLC (“TD Cowen”), the Company may offer and sell, from time to time... |
Loading...